Back to search
Publication

Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study

Abstract
Background
Many causes of vision impairment can be prevented or treated. With an ageing global population, the demands for eye health services are increasing. We estimated the prevalence and relative contribution of avoidable causes of blindness and vision impairment globally from 1990 to 2020. We aimed to compare the results with the World Health Assembly Global Action Plan (WHA GAP) target of a 25% global reduction from 2010 to 2019 in avoidable vision impairment, defined as cataract and undercorrected refractive error.

Methods
We did a systematic review and meta-analysis of population-based surveys of eye disease from January, 1980, to October, 2018. We fitted hierarchical models to estimate prevalence (with 95% uncertainty intervals [UIs]) of moderate and severe vision impairment (MSVI; presenting visual acuity from <6/18 to 3/60) and blindness (<3/60 or less than 10° visual field around central fixation) by cause, age, region, and year. Because of data sparsity at younger ages, our analysis focused on adults aged 50 years and older.

Findings
Global crude prevalence of avoidable vision impairment and blindness in adults aged 50 years and older did not change between 2010 and 2019 (percentage change −0·2% [95% UI −1·5 to 1·0]; 2019 prevalence 9·58 cases per 1000 people [95% IU 8·51 to 10·8], 2010 prevalence 96·0 cases per 1000 people [86·0 to 107·0]). Age-standardised prevalence of avoidable blindness decreased by −15·4% [–16·8 to −14·3], while avoidable MSVI showed no change (0·5% [–0·8 to 1·6]). However, the number of cases increased for both avoidable blindness (10·8% [8·9 to 12·4]) and MSVI (31·5% [30·0 to 33·1]). The leading global causes of blindness in those aged 50 years and older in 2020 were cataract (15·2 million cases [9% IU 12·7–18·0]), followed by glaucoma (3·6 million cases [2·8–4·4]), undercorrected refractive error (2·3 million cases [1·8–2·8]), age-related macular degeneration (1·8 million cases [1·3–2·4]), and diabetic retinopathy (0·86 million cases [0·59–1·23]). Leading causes of MSVI were undercorrected refractive error (86·1 million cases [74·2–101·0]) and cataract (78·8 million cases [67·2–91·4]).

Interpretation
Results suggest eye care services contributed to the observed reduction of age-standardised rates of avoidable blindness but not of MSVI, and that the target in an ageing global population was not reached.

More information

Type
Journal Article
Author
Adelson JD
Bourne RRA
Briant PS
Flaxman SR
Taylor HRB
Jonas JB
Abdoli AA
Abrha WA
Abualhasan A
Abu-Gharbieh EG
Adal TG
Afshin A
Ahmadieh H
Alemayehu W
Alemzadeh SAS
Alfaar AS
Alipour V
Androudi S
Arabloo J
Arditi AB
Aregawi BB
Arrigo A
Ashbaugh C
Ashrafi ED
Atnafu DD
Bagli EA
Baig AAW
Bärnighausen TW
Battaglia Parodi M
Beheshti MS
Bhagavathula AS
Bhardwaj N
Bhardwaj P
Bhattacharyya K
Bijani A
Bikbov M
Bottone M
Braithwaite TM
Bron AM
Burugina Nagaraja SA
Butt ZA
Caetano dos Santos FLL
Carneiro VLJ
Casson RJ
Cheng CJ
Choi JJ
Chu D
Cicinelli MVM
Coelho JMG
Congdon NGA
Couto RAA
Cromwell EAM
Dahlawi SM
Dai X
Dana R
Dandona L
Dandona RA
Del Monte MA
Derbew Molla M
Dervenis NA
Desta AAP
Deva JP
Diaz D
Djalalinia SE
Ehrlich JR
Elayedath RR
Elhabashy HRB
Ellwein LB
Emamian MH
Eskandarieh S
Farzadfar FG
Fernandes AG
Fischer FS
Friedman DSM
Furtado JM
Gaidhane S
Gazzard G
Gebremichael B
George R
Ghashghaee A
Gilani SA
Golechha M
Hamidi SR
Hammond BRR
Hartnett MERK
Hartono RK
Hashi AI
Hay SI
Hayat K
Heidari G
Ho HC
Holla R
Househ MJ
Huang JJE
Ibitoye SEM
Ilic IMD
Ilic MDD
Ingram ADN
Irvani SSN
Islam SMS
Itumalla R
Jayaram SP
Jha R
Kahloun R
Kalhor R
Kandel H
Kasa AS
Kavetskyy TA
Kayode GAH
Kempen JH
Khairallah M
Khalilov RA
Khan EAC
Khanna RC
Khatib MNA
Khoja TAE
Kim JE
Kim YJ
Kim GR
Kisa S
Kisa A
Kosen S
Koyanagi A
Kucuk Bicer B
Kulkarni VP
Kurmi OP
Landires IC
Lansingh VCL
Leasher JLE
LeGrand KE
Leveziel N
Limburg H
Liu X
Madhava Kunjathur S
Maleki S
Manafi N
Mansouri K
McAlinden CG
Meles GGM
Mersha AM
Michalek IMR
Miller TR
Misra S
Mohammad Y
Mohammadi SFA
Mohammed JAH
Mokdad AH
Moni MAA
Montasir AAR
Morse ARF
Mulaw GFC
Naderi M
Naderifar HS
Naidoo KS
Naimzada MD
Nangia V
Narasimha Swamy SM
Naveed DM
Negash HL
Nguyen HL
Nunez-Samudio VA
Ogbo FA
Ogundimu KT
Olagunju ATE
Onwujekwe OE
Otstavnov NO
Owolabi MO
Pakshir K
Panda-Jonas S
Parekh U
Park E
Pasovic M
Pawar S
Pesudovs K
Peto TQ
Pham HQ
Pinheiro M
Podder V
Rahimi-Movaghar V
Rahman MHUY
Ramulu PY
Rathi P
Rawaf SL
Rawaf DL
Rawal L
Reinig NM
Renzaho AM
Rezapour AL
Robin AL
Rossetti L
Sabour S
Safi S
Sahebkar A
Sahraian MAM
Samy AM
Sathian B
Saya GK
Saylan MA
Shaheen AAA
Shaikh MAT
Shen TT
Shibuya KS
Shiferaw WS
Shigematsu M
Shin JI
Silva JC
Silvester AA
Singh JA
Singhal DS
Sitorus RS
Skiadaresi EY
Skryabin VYA
Skryabina AA
Soheili AB
Sorrie MBARC
Sousa RARCT
Sreeramareddy CT
Stambolian DG
Tadesse EG
Tahhan NI
Tareque MI
Topouzis FX
Tran BX
Tsegaye GK
Tsilimbaris MK
Varma R
Virgili G
Vongpradith AT
Vu GT
Wang YX
Wang NH
Weldemariam AHK
West SKG
Wondmeneh TGY
Wong TY
Yaseri M
Yonemoto N
Yu CS
Zastrozhin MS
Zhang ZR
Zimsen SR
Resnikoff S
Vos T